We are live on
!
Find out more
BG
Bellevue Group Portfolio holdings
AUM
$4.75B
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
(+13%)
Cap. Flow
+$76.2M
Cap. Flow
% of AUM
1.6%
Top 10 Holdings %
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$190M |
| 2 |
Insmed
INSM
|
+$168M |
| 3 |
Gilead Sciences
GILD
|
+$130M |
| 4 |
United Therapeutics
UTHR
|
+$105M |
| 5 |
BridgeBio Pharma
BBIO
|
+$81.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Krystal Biotech
KRYS
|
+$121M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$82.6M |
| 3 |
Revolution Medicines
RVMD
|
+$72.5M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$70.4M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$63.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.91% |
| 2 | Technology | 0.03% |
| 3 | Communication Services | 0.01% |
| 4 | Consumer Discretionary | 0.01% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Ascendis Pharma A/S
ASND
$16.1B
| – | – |
-536
| Closed | -$123K |
|
152
Alibaba
BABA
$296B
| – | – |
-4,700
| Closed | -$590K |
|
153
Blackrock
BLK
$181B
| – | – |
-450
| Closed | -$433K |
|
154
BP
BP
$110B
| – | – |
-15,644
| Closed | -$735K |
|
|
CNTA
155
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-9,030
| Closed | -$359K |
|
156
Cisco
CSCO
$441B
| – | – |
-8,000
| Closed | -$621K |
|
157
Equinor
EQNR
$96.8B
| – | – |
-17,573
| Closed | -$742K |
|
158
Edgewise Therapeutics
EWTX
$4.75B
| – | – |
-1,528,518
| Closed | -$48.1M |
|
159
Inspire Medical Systems
INSP
$1.66B
| – | – |
-99,735
| Closed | -$5.14M |
|
160
JD.com
JD
$39.2B
| – | – |
-11,000
| Closed | -$325K |
|
161
Mastercard
MA
$498B
| – | – |
-1,100
| Closed | -$550K |
|
|
MASI
162
DELISTED
Masimo
MASI
| – | – |
-8,753
| Closed | -$1.56M |
|
163
Olema Pharmaceuticals
OLMA
$934M
| – | – |
-16,443
| Closed | -$245K |
|
164
Penumbra
PEN
$12.9B
| – | – |
-12,267
| Closed | -$4.03M |
|
165
Procter & Gamble
PG
$336B
| – | – |
-3,900
| Closed | -$563K |
|
166
Qiagen
QGEN
$8.88B
| – | – |
-243
| Closed | -$9.73K |
|
167
Shell
SHEL
$250B
| – | – |
-7,844
| Closed | -$729K |
|
168
Visa
V
$681B
| – | – |
-1,400
| Closed | -$423K |
|
169
Wave Life Sciences
WVE
$1.06B
| – | – |
-5,261
| Closed | -$38.1K |
|
170
ExxonMobil
XOM
$658B
| – | – |
-4,370
| Closed | -$741K |
|
|
BBOT
171
BridgeBio Oncology
BBOT
$734M
| – | – |
-6,982
| Closed | -$62.5K |
|
|
RNA
172
Atrium Therapeutics
RNA
$219M
| – | – |
-263,096
| Closed | -$3.52M |
|
Similar funds
SAMU
KCM
GCL
AA
DCP
EI
MA
SCA
Bellevue Group's Q2 2026 Portfolio in Review
As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.
- Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
- Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
- Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
- Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
- Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
- Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
- Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.
Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.